AstraZeneca Pharma India Ltd. — Interim / Quarterly Report 2022

Aug 9, 2021

August 9, 2021

The Manager - Listing BSE Limited, 1st Floor, New Trading Ring Rotunda Buiding, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager - Listing National Stock Exchange of India Ltd. Exchange plaza, 5 th Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 40005 I

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 91 2021 Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

The Board of Directors of the Company at their meeting held today i.e, August 9, 2021, has inter-alia:

• 1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 9, 2021 are enclosed herewith.
• 1. Declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22
• 1. Fixed August 20, 2021 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend

This is for your kind information and records.

Thanking you,

For AstraZeneca Pharma India 1,;11· ltl�N> Prat ra Compan Secretary & Legal

CORPORATE & REGO. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

TEL : +91 BO 6774 8000

FAX : +91 80 6774 8857

CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA

TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628

AstraZeneca Pharma India Limited

A Strates include interfed a mark of the temperature.Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045Statement of unaudited financial results for the qu

		'Re in lakhs except for camings per share data
SI No.	Particulars	3 months ended30/06/2021Unaudited	Previous 3 monthsended 31/03/2021Refer note 6	Corresponding 3months anded in theprevious year30/06/2020Unaudited	Year ended31/03/2021Audited
	a) Revenue from operations	17.540.20	21.025.71	19,357.76	81,358.38
	b) Other income	289.98	255 26	264.60	1.284.14
	Total income	17,830,18	21.280.97	19,622.56	82,640.52
$\overline{\mathbf{2}}$	Expenses
	(a) Cost of materials consumed	1,767.95	2.622.86	2.085.38	9,725.78
	(b) Purchase of stock-in-trade	3,305.66	5,698.47	4,711.22	19,474.22
	(c) Changes in inventories of finished goods, work-in-progress and	1,572.98	(669.52)	459.18	294.59
	slock-in-trade
	(d) Employee banefits expanse	5,479.34	5.249.64	5,634.75	21,954.39
	(e) Depreciation and impairmont expense	476.08	584.19	456.16	2.012 59
	(f) Allowance for expected credit loss (net)	129.25	81.47	(17.92)	271.90
	(g) Selling, marketing and distribution expense	1.028 45	1.015.14	923.88	4,520.68
	(h) Other expenses	2.693.26	2.986.68	2,704.10	11,567.69
	(i) Finance cost	26.59	28.18	27.39	109.30
	Total expenses	18,479.78	17,597.11	16,984.12	89,931.14
$\mathbf{3}$	Profit before exceptional and extraordinary items and tax (1-2)	1,350,40	3,683,86	2,638,44	12,709.38
$\blacktriangleleft$	Exceptional items
$\sf S$	Profit before extraordinary items and tax (3+4)	1,350,40	3,883.66	2,638.44	12,709.38
8	Extraordinary items
$\overline{\mathbf{r}}$	Prafit before tax (5+6)	1,350.40	3,683.86	2.038.44	12,709.38
8	Тах ехрепяе
	- Current tax	416 65	854.87	859.54	3.462.78
	- Deferred tax	(90.58)	101.10	(84.56)	(103.75)
	Total tax expense	328.07	958.97	774.97	3,379.03
9	Profit after tax (7-8)	1.024.33	2,727.89	1,863.47	9,330.35
10	Other comprehensive income/(loss)
	A Items that will not be reclassified to profit or loss
	Re-measurement gains/(losses) on post employment benefit
	obligations	(12.32)	369.25	98.16	457.98
	Income tax effect on above	3.10	(92, 33)	(2471)	(115.26)
	Total other comprehensive income/ (loss), net of income tax	(0.22)	276.32	73.48	342.70
	Total comprehensive income for the period (9+10)	1,015,11	3.004.21	1.936.93	9,673.05
11	Paid-up equity share capital	600,00	500,00	500,00	500.00
	(Face value of Rs 2/- per equity share)
12	Reserves (excluding revaluation reserves as per balance sheet)	o	s		45.117.28
13	Earnings per equity shere of Rs 2/- each (basic and diluted)	4.10	10.91	7.46	37.32

Co Chartered Acc $\mathbf{v}$ 304026E/E-30000 · Bengaluru · d

S.R.

AstraZeneca Pharma India Limited

Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited flnanclal results for the quarter ended 30 June 2021

Notes:

• The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Ad, 2013 and other recognised accounting practices and policies to the extent applicable.
• 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
• 3 The Company, which is in the business of manufacture and supply of essential goods, has been assessing the impact of the COVID-19 pandemic (including the second wa11e) on its business and beli81/es that lhe pandemic does not have a material impact oo the current or Mure operations, financial position and liquidity of the Company Management has considered all significant possible impact of known events arising from the pandemic in the preparation of these financial results. Assessing the impact of COVID-19 is, however, a continuing process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions.
• 4 During the quarter, the Company received a demand notice for an amount of Rs.15, 738.9 lakhs (and interest thereupon) under Trade Margin Rationalisation notification {"TMR notification") from National Phannaceutical Pricing Authority (NPPA) alleging overcharging of a patented anti-cancer drug sold during the period of 8 March 2019 to 31 January 2021 The said drug has been included with certain other anti-cancer medicines. on which trade margin caps are applicable under TMR notification.

Based on evaluation, Management is of the View that the TMR notification is not applicable to the aforesaid patented drug and all applicable laws relating to the pricing of the product have been complied with. The Company has filed a Writ Petition before the High Court of Delhi challenging the NPPA's demand notice. Base<I on assessment. supported by external legal advice, Management has conctuded that it has a strong case and the Company can defend its position. Accordingly, no proVision has been made in these financial results.

• 5 The Board of Directors, at its meeting dated 09 August 2021, has declared an interim dMdend of Rs. 21- per equity share aggregating to Rs 500.0/- lakhs
• 6 The iigures for the quarter ended 31 March 2021 are the balancing figures between the audited figures in respect of the lull financial year 31 March 2021 and the publlshed unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2020 which were subjected to review by the statutory auditors.
• 7 · p,esentatioo Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's for the purpose of comparability.
• 8 This subsequenHy statement of finanacial results was reviewed and recommended by the AUdit Commiltee of the Board and approved by the Board of Directors at their respective meetings held on 09 August 2021. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2021.

By Order of the B011rd of Directors For Ast eneca Pharma India Limited

� ,. ' Gaga I g Bedi Mana Ir r

)

Place: Bengaluru Oats: 09 August, 2021

Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To The Board of Directors AstraZeneca Pharma India Limited Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru - 560 045

• 1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2021 which are included in the accompanying 'Statement of unaudited financial results for the quarter ended June 30, 2021" and the notes thereon (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
• 1. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
• 1. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
• 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026£/ E-300009

........ . .

J�Qg,i�.�.� D

Partner Membership Number: 206477 UDIN: 21206477AAAAAY8916

Place: Bengaluru Date: August 09, 2021

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road Wsoor, Bangalore-560 008

... , ... ,. ·-�················· -........ -... , .......................... ,.·-··�··············· ..................................................... , ..... ' ... ........................................................ , .....

T:+91 (Bo) 4079 5000, F:+91 (Bo) 4079 5222

Registered office and Head office: Plot No. Y -14. Block EP, Sector V, Sall Lake Electronic Complex, Bidhan Nagar. Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Llablllty Partnership with LLP Identity no: LLPIN AA�362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)